

IFW


TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))				Docket No. PN0301	
In Re Application Of: Knut-Egil Loekling, et.al.					
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/753,929	01/08/2004	To Be Assigned	36335	1614	5513
Title: pH-Sensitive Liposomes					
Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450					
37 CFR 1.97(b)					
1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.					
37 CFR 1.97(c)					
2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:					
<div style="margin-left: 40px;"> <input type="checkbox"/> the statement specified in 37 CFR 1.97(e); </div>					
OR					
<div style="margin-left: 40px;"> <input type="checkbox"/> the fee set forth in 37 CFR 1.17(p). </div>					

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
PN0301

In Re Application: Knut-Egil Loekling, et.al.

AUG 09 2004



Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/753,929	01/08/2004	To Be Assigned	36335	1614	5513

pH-Sensitive Liposomes

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☐ The Director is hereby authorized to charge and credit Deposit Account No. _____ as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☐ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on Aug. 5, 2004 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Signature of Person Mailing Correspondence

Lori B. Allaire

Typed or Printed Name of Person Mailing Certificate

***This certificate may only be used if paying by deposit account.**


Signature

Dated: 8/5/04

Li Cai
Reg. No. 45,629
Amersham Health, Inc.
101 Carnegie Center
Princeton, NJ 08540
(609) 514-6418

CC:

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
PN0301SERIAL NO.
10/753,929INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Knut-Egil LoeklingFILING DATE
01/08/2004GROUP
1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4426330	01-1984	Sears			
	6426086	07-2002	Papahadjopoulos, et.al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	99/52505	10-1999	WO				
	96/23526	08-1996	WO				
	98/33520	08-1998	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	D. Collins, et.al., Biochem Biophys. Acta 1025 (1990), 234-242
	K.-E. Lokling, et.al., Magn. Reson. Imaging 19 (2001), 731-738
	D.D. Lasic, Preparation of liposomes, in D.D. Lasic (ed) Liposomes from physics to applications, Amsterdam, Elsevier Science Publishers B.V., The Netherlands 1993, p. 67-107
	J.T. Mason, et.al., Biochemistry 29, (1990), 590-598

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. PN0301	SERIAL NO. 10/753,929
	APPLICANT Knut-Egil Loekling	
	FILING DATE 01/08/2004	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	J.T. Mason, et.al., Anal. Biochem. 113 (1980), 96-101
	K Ng, et.al., Int. J. Pharm 193: (2000) 157-166
	D. Collins et.al., Biochem Biophys. Acta 987/1 (1989) 47-55
	D.R. Kodali et.al., Chem. Phys. Lipids 61(2), 1992 169-173
	Database dissertation asbtracts onlinde, Tari, Ana Maria : « Studies on bilayer liposomes composed of 1,2-diacyl-3-succinyglycerol (destabilization, serum albumin, liver)", abstract of Ph.D. thesis (1992)
	Database dissertation asbtracts ondine, Liu, Dexi: "PH-sensitive liposomes from test tube to animal model", abstract of Ph.D. thesis (1990)
	Database dissertation abstracts online, Collins, David Samuel: "Mechanism of destabilizationof pH-sensitive liposomes and implications for cellular delivery", abstract of PH.D. thesis (1989)
	Liu, D, et.al., Biochim. Biophys. Acta- Biomembranes 1990 Netherlands 1022/3 (1990), 348-354
	Leventis, R., et.al., Biochemistry 26/12 (1987), 3267-3276
	Simoes, S. et.al., Biochim. Biophys. Acta 1515/1(2001), 23-37
	Moghimi, S.M. et.al., Pharmacological Reviews 53/2 (2001), 283-318
	Hafez, I.M. et.al., Biophysical Journal 79/3 (2000), 1438-1446
	European Search report for EP application 04000310.5 dated June 29, 2004

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.